Thyroid Carcinoma, Version 2.2014 Featured Updates to the NCCN Guidelines
Thyroid Carcinoma, Version 2.2014 Featured Updates to the NCCN Guidelines
复制标题
DOI：
10.6004/jnccn.2014.0169
复制
发表时间：
2014-12-01
影响因子：
13.4
通讯作者：
Hughes, Miranda
中科院分区：
文献类型：
--
作者：
Tuttle, R. Michael;Haddad, Robert I.;Hughes, Miranda
这些 NCCN 指南见解重点关注 2014 年 NCCN 甲状腺癌指南的一些主要更新。激酶抑制剂疗法可用于治疗有症状和/或进行性且不适合用放射性碘治疗的甲状腺癌。索拉非尼可考虑用于特定的转移性分化型甲状腺癌患者，而凡德他尼或卡博替尼可推荐用于特定的转移性甲状腺髓样癌患者。对于患有这两种类型的甲状腺癌的特定患者，可以考虑使用其他激酶抑制剂。 NCCN 指南中添加了“晚期甲状腺癌激酶抑制剂治疗原则”的新章节，以协助使用这些新型靶向药物。
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/ or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on " Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.